Nkarta (NKTX) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nkarta (NKTX) has outperformed Tiziana Life Sciences (TLSA) over the past year, gaining 6.2% versus a loss of 50.7%. Over five years, TLSA leads with a -25.2% price change compared with -87.9% for NKTX. Nkarta is the larger company by market cap ($161.2 million vs $151.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NKTX | TLSA |
|---|---|---|
| Share price | $2.25 | $1.19 |
| Market cap | $161.16M | $151.44M |
| 1-day change | +1.35% | +5.31% |
| YTD return | +20.00% | -24.16% |
| 1-year return | +6.22% | -50.66% |
| 5-year return | -87.90% | -25.17% |
| EPS (TTM) | $-1.58 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.72 | $2.25 |
| 52-week low | $1.70 | $0.76 |
| Distance from 52-week high | -39.52% | -47.11% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +381.33% | +570.59% |
| Average volume | 613.16K | 720.16K |
| Shares outstanding | 71.62M | 127.26M |
| Employees | 106 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NKTX has outperformed TLSA by 56.9 percentage points over the past year.
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
NKTX vs TLSA FAQ
Which is bigger, Nkarta or Tiziana Life Sciences?
Nkarta (NKTX) is larger, with a market capitalization of $161.16M compared with $151.44M for Tiziana Life Sciences (TLSA).
Which stock has performed better over the past year, NKTX or TLSA?
NKTX returned +6.22% over the past 12 months, compared with -50.66% for TLSA (price return, excluding dividends). Past performance does not predict future results.
Are Nkarta and Tiziana Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.